Metsera, Inc.
MTSR
Hisse Senetlerindeki Sıralama
#2571
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Hisse Fiyatı
$70.50
Son senkronizasyon: 2025-11-14
Piyasa Değeri
$7.33B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
33.60%
Ülke
US
Ticaret Metsera, Inc. (MTSR)
Kategori
Healthcare
Metsera, Inc. (MTSR) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $72.34 - 2025-11-01
Gün sonu en düşük fiyat: $26.50 - 2025-01-01
Gün sonu en düşük fiyat: $26.50 - 2025-01-01
Metsera, Inc. için hisse fiyatı geçmişi: 2025 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | -10.54% |
| 2025 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $763.31 | 8.49% |
CH
|
